GlassScriptPhysician profile
Amy Jo Freeman
NPI 1295372233
$7,474.57
in general payments reported to CMS, 2019-2025
41 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $1,673 · 2023: $1,739 · 2024: $1,651 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,204.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,539.71 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $931.23 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $557.34 | 2021-2024 | Ultomiris |
| Pfizer INC. | $545.36 | 2023-2025 | |
| Ucb, INC. | $425.02 | 2021-2025 | Rystiggo, Briviact, Zilbrysq |
| Biogen, INC. | $424.21 | 2021-2025 | Vumerity, Tysabri |
| Lundbeck LLC | $343.53 | 2021-2025 | Vyepti |
| Emd Serono, INC. | $274.84 | 2022-2024 | Mavenclad |
| Amgen INC. | $241.57 | 2022-2025 | Uplizna |
| Springworks Therapeutics, INC. | $216.08 | 2024-2025 | Gomekli |
| Lilly USA, LLC | $178.63 | 2022-2024 | Emgality, Reyvow |
| Neurelis, INC. | $161.44 | 2021-2025 | Valtoco |
| Amneal Pharmaceuticals LLC | $159.16 | 2022-2025 | Rytary, Crexont |
| Neurocrine Biosciences, INC. | $149.14 | 2021-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $124.24 | 2021-2025 | Ajovy, Austedo Xr, Austedo Xr |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $109.79 | 2021 | |
| Genentech USA, INC. | $89.43 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Sk Life Science, INC. | $89.26 | 2022-2025 | |
| Argenx US, INC. | $85.35 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Tg Therapeutics, INC. | $81.24 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $74.80 | 2022-2025 | Wainua |
| Tanabe Pharma America, INC. | $60.26 | 2022-2024 | |
| Avion Pharmaceuticals | $55.31 | 2022-2023 | Dhivy |
| Banner Life Sciences, LLC | $55.29 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $52.68 | 2023 | Rexulti |
| Biohaven Pharmaceutical Holding Company LTD. | $50.34 | 2022 | |
| Supernus Pharmaceuticals, INC. | $49.10 | 2021-2022 | |
| Kyowa Kirin, INC. | $44.99 | 2022-2024 | Nourianz |
| Eisai INC. | $42.07 | 2021-2022 | |
| Genzyme Corporation | $36.55 | 2023 | |
| Sunovion Pharmaceuticals INC. | $36.01 | 2021 | |
| Catalyst Pharmaceuticals, INC. | $30.37 | 2024 | |
| Nevro Corp. | $27.85 | 2022-2023 | Senza |
| Merz Pharmaceuticals, LLC | $21.76 | 2025 | Ampyra, Inbrija, Xeomin |
| Averitas Pharma INC. | $21.14 | 2023 | Qutenza |
| Scilex Pharmaceuticals INC. | $17.10 | 2025 | |
| Mdd US Operations, LLC | $17.05 | 2024 | Gocovri |
| Acadia Pharmaceuticals INC | $14.99 | 2025 | Nuplazid |
| Alnylam Pharmaceuticals INC. | $14.35 | 2023 | Onpattro |
| Currax Pharmaceuticals LLC | $13.22 | 2024 | Onzetra Xsail |
| Livanova USA, INC. | $12.77 | 2023 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.